Entera Bio (ENTX) Income from Continuing Operations (2019 - 2026)
Entera Bio (ENTX) posted quarterly Income from Continuing Operations of 3611000.0 for Q1 2026, down 37.88% year-on-year from 5812666.87 in Q1 2025, and down 15.07% on a QoQ basis from 3138000.0 in Q4 2025.
Entera Bio (ENTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has reported Income from Continuing Operations for 8 consecutive years, with 3611000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations fell 37.88% year-over-year to 3611000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12913000.0 (down 23.77% YoY) and the FY2025 annual result came in at 11439000.0, down 19.89% from the prior year.
- Income from Continuing Operations declined to 3611000.0 in Q1 2026 per ENTX's latest filing, from 3138000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ENTX reached as high as 1995000.0 in Q4 2023 and fell as low as 3784000.0 in Q1 2022.
- A 5-year average of 2786352.94 and a median of 2732000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 64.81% — and 2023, when it jumped 42.12%.
- Year by year, Income from Continuing Operations stood at 3035000.0 in 2022, then surged by 34.27% to 1995000.0 in 2023, then dropped by 18.2% to 2358000.0 in 2024, then sank by 33.08% to 3138000.0 in 2025, then decreased by 15.07% to 3611000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3611000.0, 3138000.0, and 3432000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | -3.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.61 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -3.43 Mn |
| Jun 30, 2025 | -2.73 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Dec 31, 2024 | -2.36 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -2.44 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -2.38 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.19 Mn |
| Dec 31, 2022 | -3.04 Mn |
| Sep 30, 2022 | -3.07 Mn |
| Jun 30, 2022 | -3.19 Mn |
| Mar 31, 2022 | -3.78 Mn |
| Dec 31, 2021 | -4.10 Mn |
| Sep 30, 2021 | -3.21 Mn |
| Jun 30, 2021 | -2.58 Mn |